Published • loading... • Updated
AstraZeneca Shares Tumble 7% After Reported Bristol Myers Talks: Reuters
The proposed deal could create a company worth more than £300 billion and face major antitrust scrutiny, sources said.
- AstraZeneca held merger talks with New York-listed Bristol Myers Squibb, The Financial Times reported on Monday, with a potential combination valued at more than £300 billion.
- Under CEO Sir Pascal Soriot, AstraZeneca has aggressively pursued U.S. expansion, completing a direct listing on the New York Stock Exchange this year to bolster its American footprint.
- IG chief market analyst Chris Beauchamp said "Companies saying one thing and doing another is a well-trodden path," noting AstraZeneca recently claimed it did not need M&A to hit targets.
- A potential merger faces significant antitrust scrutiny, while overlapping cancer immunotherapy drugs—Bristol Myers' Opdivo and AstraZeneca's Imfinzi—present regulatory and operational hurdles.
- Sources warned the deal "may be delayed or fall apart," though if completed, it would create the world's fourth-largest pharmaceutical company worth more than £300 billion.
Insights by Ground AI
Podcasts & Opinions
18 Articles
18 Articles
Coverage Details
Total News Sources18
Leaning Left1Leaning Right2Center7Last UpdatedBias Distribution70% Center
Bias Distribution
- 70% of the sources are Center
70% Center
C 70%
R 20%
Factuality
To view factuality data please Upgrade to Premium
